NEW YORK, NY / ACCESS Newswire / March 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Fintel reports that on March 7, 2025, Stifel downgraded their outlook for Neumora Therapeutics (NasdaqGS:NMRA) from Buy to ...

Neumora Therapeutics (NASDAQ:NMRA – Get Free Report)‘s stock had its “sector perform” rating reaffirmed by investment ...

The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that a securities class action lawsuit has been fil ...

KOASTAL-2 and -3 studies optimized based on learnings from KOASTAL-1; topline data expected from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Topline data from NMRA-511 ...

Equities researchers at William Blair increased their Q1 2025 earnings per share (EPS) estimates for shares of Neumora Therapeutics in a report released on Monday, March 3rd. William Blair analyst M.

Neumora Therapeutics (NASDAQ:NMRA) stock drops 11% as Stifel downgrades nothing that J&J (JNJ) discontinues a drug similar to NMRA's lead asset. Read more here.

Robert Lenz is leaving the brain drug developer to “pursue other interests.” Elsewhere, Atara is cutting half of its staff ...

Neumora Therapeutics (NMRA) surprised investors in its Q4 2024 earnings call by reporting an earnings per share (EPS) of -$0.37, surpassing the forecasted -$0.62. This unexpected result led to a ...

March 03, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs ...